Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.49 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | TNKS | O95271 | 1/20 | 0.40 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.39 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.38 |
| ▸ | ACP1 | P24666 | 2/20 | 0.37 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | PARP1 | P09874 | 1/20 | 0.35 |
| ▸ | PDE5A | O76074 | 1/20 | 0.34 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2996550 | 0.77 | PDE10A (0.40) | ALDH1A1NUDT1NPC1MEN1KMT2A | |
| SCHEMBL12504960 | 0.74 | AR (0.51) | ALDH1A1TNKSNPC1MEN1KMT2A | |
| SCHEMBL16720376 | 0.73 | NPC1 (0.50) | ALDH1A1NPC1MEN1KMT2APDE5A | |
| SCHEMBL8637618 | 0.71 | GSTP1 (0.40) | ALDH1A1TSHRNPC1MEN1KMT2A | |
| SCHEMBL5915632 | 0.67 | TAAR1 (1.00) | TAAR1HRH3ALDH1A1TSHRTNKS | |
| SCHEMBL21195921 | 0.67 | PDGFRB (0.49) | ALDH1A1NPC1 | |
| SCHEMBL12679031 | 0.67 | HRH3 (1.00) | TAAR1HRH3ALDH1A1TSHRTNKS | |
| SCHEMBL6499308 | 0.66 | PDGFRB (0.51) | ALDH1A1NPC1PIK3CD | |
| SCHEMBL27588463 | 0.66 | HRH3 (0.52) | TAAR1HRH3ALDH1A1TSHRTNKS | |
| SCHEMBL3986805 | 0.66 | NPC1 (0.59) | ALDH1A1TSHRNPC1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9120749-B2 | Quinoline derivatives and MELK inhibitors containing the same | ONCOTHERAPY SCIENCE, INC. (JP) | 2015-09-01 | — | — | US | disclosed |
| US-20130217671-A1 | QUINOLINE DERIVATIVES AND MELK INHIBITORS CONTAINING THE SAME | ONCOTHERAPY SCIENCE, INC. (JP) | 2013-08-22 | — | — | US | disclosed |
| EP-2597955-A1 | QUINOLINE DERIVATIVES AND MELK INHIBITORS CONTAINING THE SAME | OncoTherapy Science, Inc. (JP) | 2013-06-05 | — | — | EP | disclosed |
| WO-2012016082-A1 | QUINOLINE DERIVATIVES AND MELK INHIBITORS CONTAINING THE SAME | ONCOTHERAPY SCIENCE, INC. (JP) | 2012-02-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130217671-A1 | QUINOLINE DERIVATIVES AND MELK INHIBITORS CONTAINING THE SAME | MELK, NADK, NEK1 | TAAR1 2800/4885HRH3 1890/4885ALDH1A1 2754/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.